Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2NET 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 2Vaginal Neoplasms 1Neuroendocrine Tumors 1

Interventions

pembrolizumab 110Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 50Cyclophosphamide 50Paclitaxel 48durvalumab 38Radiation 37Gemcitabine 37olaparib 32Rituximab 32Etoposide 32Dexamethasone 32Doxorubicin 30Docetaxel 30atezolizumab 28Lenalidomide 27Ipilimumab 27Taxes 26Pemetrexed 25Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Radiotherapy, Intensity-Modulated 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 90 days × Clear all
NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT02466971 2026-05-29

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

National Cancer Institute (NCI)

Phase 3 Active not recruiting
450 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02595879 2026-05-29

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
21 enrolled 22 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡